K Ganda1, A Schaffer, M J Seibel. 1. Bone Research Program, ANZAC Research Institute, The University of Sydney, Sydney, Australia, kgan7206@uni.sydney.edu.au.
Abstract
SUMMARY: This 7-year prospective observational study determined the predictors of re-fracture amongst 234 patients managed within a Secondary Fracture Prevention programme. Poor compliance, multiple co-morbidities, corticosteroid therapy, low hip bone mineral density (BMD) or low body weight were all significantly associated with re-fracture in patients commenced on long-term anti-resorptive therapy. INTRODUCTION: Risk factors for osteoporotic fracture amongst treatment-naïve patients are well established. In contrast, predictors of re-fracture in patients optimally managed within a Secondary Fracture Prevention (SFP) programme are ill-defined. METHODS: This prospective observational study included 234 subjects with incident osteoporotic fractures managed long-term by the Concord SFP programme. Using Cox proportional hazards models, predictors of re-fracture were analysed separately for patients commenced on specific pharmacotherapy (group 1, N=171) and subjects receiving calcium and/or vitamin D supplements only (group 2, N=63). Relevant anthropometric, clinical and technical data were documented at each visit. Compliance and persistence were analysed as time-varying covariates. RESULTS: During a mean follow-up of 5.2 (range 3.5-7.3) years, 20.9% of all subjects re-fractured (26.3% in group 1, 6.3% in group 2). Multivariate predictors of re-fracture in group 1 were significant co-morbidity (HR 2.04 if >3, 95% CI 1.10-3.79, p=0.024), corticosteroid use (HR 1.75, 95% CI 1.12-2.73, p=0.013) and total hip BMD (HR 1.36 per 0.1 g/cm2 decrease, 95% CI 1.08-1.70, p=0.008). In contrast, gender, prevalent fractures and lumbar spine BMD were not associated with re-fracture. Amongst patients with complete compliance data, a medication possession ratio of ≤50% (HR 3.36, 95% CI 1.32-8.53, p=0.011) and low body weight (HR 1.04 per 1-kg decrease, 95% CI 1.003-1.08, p=0.032) were significantly associated with re-fracture. CONCLUSIONS: Amongst patients managed within a dedicated SFP programme, poor compliance, multiple co-morbidities, corticosteroid therapy, low hip BMD or low body weight are all associated with increased risk of re-fracture. This subgroup of patients therefore require intensive management including strategies to improve compliance.
SUMMARY: This 7-year prospective observational study determined the predictors of re-fracture amongst 234 patients managed within a Secondary Fracture Prevention programme. Poor compliance, multiple co-morbidities, corticosteroid therapy, low hip bone mineral density (BMD) or low body weight were all significantly associated with re-fracture in patients commenced on long-term anti-resorptive therapy. INTRODUCTION: Risk factors for osteoporotic fracture amongst treatment-naïve patients are well established. In contrast, predictors of re-fracture in patients optimally managed within a Secondary Fracture Prevention (SFP) programme are ill-defined. METHODS: This prospective observational study included 234 subjects with incident osteoporotic fractures managed long-term by the Concord SFP programme. Using Cox proportional hazards models, predictors of re-fracture were analysed separately for patients commenced on specific pharmacotherapy (group 1, N=171) and subjects receiving calcium and/or vitamin D supplements only (group 2, N=63). Relevant anthropometric, clinical and technical data were documented at each visit. Compliance and persistence were analysed as time-varying covariates. RESULTS: During a mean follow-up of 5.2 (range 3.5-7.3) years, 20.9% of all subjects re-fractured (26.3% in group 1, 6.3% in group 2). Multivariate predictors of re-fracture in group 1 were significant co-morbidity (HR 2.04 if >3, 95% CI 1.10-3.79, p=0.024), corticosteroid use (HR 1.75, 95% CI 1.12-2.73, p=0.013) and total hip BMD (HR 1.36 per 0.1 g/cm2 decrease, 95% CI 1.08-1.70, p=0.008). In contrast, gender, prevalent fractures and lumbar spine BMD were not associated with re-fracture. Amongst patients with complete compliance data, a medication possession ratio of ≤50% (HR 3.36, 95% CI 1.32-8.53, p=0.011) and low body weight (HR 1.04 per 1-kg decrease, 95% CI 1.003-1.08, p=0.032) were significantly associated with re-fracture. CONCLUSIONS: Amongst patients managed within a dedicated SFP programme, poor compliance, multiple co-morbidities, corticosteroid therapy, low hip BMD or low body weight are all associated with increased risk of re-fracture. This subgroup of patients therefore require intensive management including strategies to improve compliance.
Authors: Ann Cranney; Alexandra Papaioannou; Nicole Zytaruk; David Hanley; Jonathan Adachi; David Goltzman; Timothy Murray; Anthony Hodsman Journal: CMAJ Date: 2006-07-04 Impact factor: 8.262
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Lisa Langsetmo; David Goltzman; Christopher S Kovacs; Jonathan D Adachi; David A Hanley; Nancy Kreiger; Robert Josse; Alexandra Papaioannou; Wojciech P Olszynski; Sophie A Jamal Journal: J Bone Miner Res Date: 2009-09 Impact factor: 6.741
Authors: Somnath Sarkar; Jean-Yves Reginster; Gerald G Crans; Adolfo Diez-Perez; Karen V Pinette; Pierre D Delmas Journal: J Bone Miner Res Date: 2003-12-22 Impact factor: 6.741
Authors: J T Harrington; L-G Ste-Marie; M L Brandi; R Civitelli; P Fardellone; A Grauer; I Barton; S Boonen Journal: Calcif Tissue Int Date: 2003-12-05 Impact factor: 4.333
Authors: Daniel Prieto-Alhambra; Aina Pagès-Castellà; Gemma Wallace; M Kassim Javaid; Andrew Judge; Xavier Nogués; Nigel K Arden; Cyrus Cooper; Adolfo Diez-Perez Journal: J Bone Miner Res Date: 2014-01 Impact factor: 6.741
Authors: Lisanne Vranken; Caroline E Wyers; Joop P W van den Bergh; Piet P M M Geusens Journal: Calcif Tissue Int Date: 2017-05-24 Impact factor: 4.333
Authors: L Vranken; C E Wyers; R Y Van der Velde; H M Janzing; S Kaarsemaker; P P Geusens; J P Van den Bergh Journal: Osteoporos Int Date: 2017-11-23 Impact factor: 4.507